fda bpc 157 warning letter unapproved drug Targets GLP-1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling FDA issued 25 warning letters
Description
FAQs About AOD-9604 Benefits FAQs About AOD-9604 Benefits What is the main benefit of AOD-9604
The expectation is informed extrapolation, not a published headline

2013 Jun;88(6):522-6
Semaglutide (Wegovy and Ozempic) is an FDA-approved GLP-1 agonist that is used to treat obesity, type 2 diabetes, and weight-related health conditions such as metabolic dysfunction-associated steatohepatitis (MASH)

Study using DAF-FM fluorescent dye revealed a 1.35-fold increase of nitric oxide induced in vascular endothelial cells by 1.0 g/ml BPC 157 which contributed to the enhanced cell migration
We do know that pesticides also indirectly and unintentionally kill other living organisms